ATEA Pharmaceuticals, Inc.
Clinical trials sponsored by ATEA Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing antiviral therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
- Can a new drug tame hepatitis e? a first human trial begins Results expected Dec 2026 (estimated)
- New hep c combo aims to match top therapy in phase 3 showdown Results expected Dec 2026 (estimated) 🚀 Make-or-break
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThis study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…
Phase 3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hepatitis c pill aims to cut treatment time in half
Disease control OngoingThis Phase 3 trial compares a new two-drug combination pill (Bemnifosbuvir-Ruzasvir) against the current standard treatment (Sofosbuvir-Velpatasvir) for adults with chronic hepatitis C. About 880 participants who have not been treated with similar drugs before will take the new p…
Phase 3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC